PRIMARY orbital meningiomas arising from the optic nerve dural sheath are called ONSMs. They typically grow by spreading circumferentially along the optic nerve, leading to nerve atrophy due to compression and failure of the pial blood supply. They can be located on the orbital or canalicular portion of the optic nerve. The latter type is typically detected early when it causes compression within the optic canal, but the former may grow large while visual deficits progress slowly. Bilateral visual deficits may be caused by direct extension or by traction and distortion of the optic chiasm (Fig. 1).

The most common symptoms of ONSMs are loss of vision and exophthalmos. In particular, progressive loss of visual acuity or visual fields is present in nearly all the cases examined, even when the lesion is small. The most common visual field defect is peripheral constriction. Early stages of compressive neuropathy usually manifest as dyschromatopsia, afferent pupillary defects, and optic disc edema, which may lead to optic atrophy. Opticociliary shunt vessels are a late sign of compressive optic neuropathy and are often associated with exophthalmos. The triad of progressive painless visual loss, optic nerve atrophy, and opticociliary shunt vessels is rare but virtually pathognomonic for the diagnosis of ONSM.

Clinical Management of ONSMs

Because ONSMs and the symptoms they cause progress slowly, conservative management has often been advocated; treatment may be deferred until evidence of progression is found. This “wait and see” approach is reinforced by the high likelihood of vision loss after microsurgical resection. Conventional radiotherapy is more likely to preserve vision but is less likely than surgery to produce local tumor growth control. Radiosurgery is also associated with a risk of radionecrosis and radiation-induced neuropathy of cranial nerves.

This conservative approach, which has dominated the field over the last 60 years, can be challenged based on good results recently reported using stereotactic techniques of radiation delivery. Growing evidence supports the use of fractionated stereotactic radiation therapy in the management of symptomatic ONSMs. Single-session (Gamma Knife or LINAC-based) radiosurgery has rarely been offered as treatment for ONSMs because it is feared that effective treatment doses would not be tolerated by the optic nerve. Recent reports suggest, however, that effective single-session radiosurgery may be tolerated (J Adler, personal communication). Recent technical innovations have eliminated the stereotactic frame that has generally been

Abbreviations used in this paper: CT = computed tomography; LINAC = linear accelerator; MR = magnetic resonance; ONSM = optic nerve sheath meningioma; SFRT = stereotactic fractionated radiotherapy.
used for single-session radiosurgery, thereby making multisession radiosurgery a feasible alternative. Delivering high radiation doses stereotactically in multiple sessions may provide ONSM growth control in association with increased probability of sparing vision. Preliminary experience treating ONSMs with multisession CyberKnife radiosurgery, which we review below, appears quite promising.

Microsurgical Treatment

Encasement of the optic nerve by an ONSM (Fig. 1) makes it impossible to obtain a radical resection without causing severe injury to the nerve itself or to its vascular supply, which is completely shared by the tumor. As a consequence, vision preservation following microsurgical resection of ONSMs is rare. Some experienced surgeons believe that excision invariably leads to blindness. As a general attitude toward the most common type of ONSMs, a fusiform sheath growing around the optic nerve, most surgeons do not even attempt to dissect the nerve but directly proceed to the resection of the nerve and the tumor together. Nerve preservation in these cases is clearly impossible.

Optic nerve sheath meningiomas confined in the orbit are resected via an orbitotomy. Orbital exenteration is performed when the orbit is invaded by tumor beyond the optic nerve. For meningiomas extending into the optic canal from within the skull, surgical unroofing is the preferred treatment. The surgical approach in this situation depends on the location of the meningioma in relation to the optic nerve. Craniotomy is required in cases of intracranial extension. En bloc resection of the optic nerve is likely to be the best strategy in patients in whom functional vision is lost, especially if there is extensive intracranial extension. Surgery is important also in patients with disfiguring exophthalmos and blindness. Young patients with good vision may harbor meningiomas that behave more aggressively and thus carry a poor prognosis. In these cases the risk of chiasmal involvement and bilateral loss of vision should be contemplated and early surgery may be attempted.

Stereotactic Fractionated Radiation Therapy

Stereotactic fractionated radiation and conformal radiotherapy have been used increasingly to treat ONSMs. Favorable short-term results have been published, and primary SFRT has been advocated to preserve vision in patients with ONSM rather than undertaking observation alone. Some authors assume that SFRT will become a standard treatment approach for ONSM. Stereotactic fractionated radiotherapy produces conformal dose distributions with consequent substantial sparing of surrounding normal tissues and is clearly a more sophisticated and safer treatment option than conventional radiotherapy. On the other hand, it does not reach the extremely tight dose distribution typical of radiosurgery and may still allow dose leaking over the retina and other nearby structures. As a consequence, radiation retinopathy, loss of vision, and endocrine failure may still occur after SFRT for ONSMs. Radiation optic neuropathy has also been described after low-dose treatment (40–45 Gy delivered at < 2 Gy/fraction) of pituitary lesions. Furthermore, several other long-term ophthalmic and adnexal complications following external-beam radiotherapy and SFRT have been described.

Frameless Image-Guided Robotic Radiosurgery

Technological Overview

The CyberKnife is a frameless 6 MV LINAC system for image-guided robotic radiosurgery (Fig. 2). Real-time image guidance based on digitally reconstructed skull radiographs is used to localize and treat the targeted site. The robotic arm provides great flexibility and the highest number of noncoplanar penetration trajectories (≥ 1600 with the new G4 model). Radiation is delivered with submillimetric accuracy. The system presumes a fixed relationship between the target and the skull, as with other forms of stereotaxy. A light-weight 6-MV LINAC is accurately positioned by a robotic arm with 6 degrees of freedom. Two x-ray imaging devices positioned on either side of the patient’s anatomy acquire real-time digital radiographs of the skull at repeated intervals during treatment. Amorphous silicon sensors create a high-quality image of the skull or spine with a modest exposure to radiation (10 mA, 75 kV; corresponding to a dose per image of ~ 25 mrad).

The images acquired during the treatment are automatically registered to digitally reconstructed radiographs derived from the treatment planning CT scans. This registration process allows the position of the skull (and thus the
treatment site) to be translated to the coordinate frame of the LINAC. A control loop between the imaging system and the robotic arm adjusts the pointing of the LINAC therapeutic beam to the observed position of the treatment anatomy (target). If the patient moves, the change is detected during the next imaging cycle and the beam is adjusted and realigned.

CyberKnife Treatment of Optic Pathway Lesions

The CyberKnife offers 2 distinct advantages in the treatment of optic pathway lesions, both stemming from the absence of a rigid frame. Real-time image guidance based on digital 6D reconstruction of radiographic images of the skull provides accurate beam delivery for either single- or multisession treatments. By delivering treatment in multiple sessions it is possible to exploit the differential speed of recovery of normal and pathological tissues, thereby limiting or avoiding damage to the visual pathways while controlling tumor growth. Furthermore, many more trajectories are available due to the absence of a rigid frame blocking the access of beams through the basicranium and the facial bones (Fig. 3). These additional beam penetration trajectories, which are not available in the presence of a rigid frame attached at the level of the orbitomeatal line, provide enhanced dose conformality and homogeneity while greatly reducing the number of beams crossing the brain. Inverse planning software is used to optimize target coverage and achieve tightly conformal isodose distributions with substantial sparing of surrounding brain tissue (Fig. 3). Nonisocentric beam delivery (as opposed to isocentric multishot technology) also enables a significant measure of dose homogeneity.

Multisession treatment protocols involving the CyberKnife to treat optic pathway lesions have been reported to result in excellent rates of tumor control or arteriovenous malformation obliteration and good preservation of vision.

Multisession CyberKnife Radiosurgery for ONSMs

Radiosurgical treatment of anterior visual pathway lesions is an especially challenging task due to the peculiar radiation sensitivity of the optic nerve chiasm and tracts. On the basis of the preliminary experience in the treatment of optic pathway lesions reported by the Stanford CyberKnife team led by John Adler, multisession CyberKnife radiosurgery was offered to 3 of our patients with ONSMs. The diagnosis was based on neuroimaging; no biopsy sample was obtained. The tumor originated from the orbital segment of the optic nerve in 2 patients and from the canalicular segment in 1. Presenting symptoms included visual field deficits, loss of visual acuity, and exophthalmos associated with opticociliary shunt vessels (Table 1). A slow but appreciable worsening of visual complaints occurred in all 3 patients in the absence of a clear growth of the lesion on serial neuroimaging. However, surgery was deferred due to the presence of residual visual function, and the patients were offered the option of undergoing multisession CyberKnife treatment based on the good results in treating visual pathway lesions following the Stanford multisession protocol. The patients underwent thin-slice (1.25-mm-thick) CT scanning after intravenous injection of contrast medium, as well as volumetric MR imaging. The studies were fused and the targets identified. In all 3 cases, side-by-side comparison of the studies showed that the contrast-enhanced CT scans were a sufficient and satisfactory study to identify the nerve and the tumor. It was therefore possible to draw the target directly on the CT scans, which probably increased substantially the accuracy of the
treatment because the error introduced by the distortion in MR studies was avoided, as was the further error induced by CT–MR image fusion. The optic nerve was found to be embedded in the tumor in 1 case (Case 2 in Table 1; also see Fig. 1), whereas in the other 2 cases the optic nerve appeared as a marginal structure compressed and displaced by the tumor. In the latter 2 cases the nerve was drawn out as a critical structure during treatment planning and, despite the proximity to the tumor, a treatment plan that minimized the dose delivered to the optic nerve was created. Care was taken to limit the maximum dose to $\frac{30}{1021}$ Gy and to obtain a tightly conformal and homogeneous dose distribution. Particular care was also taken to reduce to a minimum the radiation dose to the lens, retina, and optic nerve beyond the margins of the tumor. An 80% prescribed isodose of 20 Gy was delivered in 4 sessions of 5 Gy, each lasting ~25 minutes and separated by a 24-hour interval. Dexamethasone (4 mg) was administered after each session. No further steroid agents were required during follow-up.

Follow-up consisted of MR imaging (every 6 months) and visual field and acuity examinations (every 3 months). No changes in lesion size were observed over time on serial images. Progressive improvement in visual fields and acuity was documented in all 3 patients. After 1 year, full restoration to normal vision was diagnosed by independent ophthalmologists assessing these patients. Visual fields and acuity restoration have remained stable 42, 32 and 30 months, respectively, since the procedure. Figure 3 illustrates treatment planning in Case 1, and Fig. 4 illustrates visual fields before and 36 months after radiosurgery. This case is characterized by bilateral visual field impairment (left more than right) presumably related to the attraction and distortion of the optic chiasm caused by the tumor (Fig. 3). Bilateral improvement was noted after 6 months with full recovery visible after 12 months, and this status was maintained at 36 months. In terms of restoration of visual fields and acuity, similar results were also found in the other 2 patients, including the 1 with exophthalmos. This latter patient also experienced remission of the optociliary shunting approximately 1 year after the treatment in association with slightly reduced exophthalmos. The clinical outcome, including visual restoration, in this latter case was particularly interesting in view of the larger volume of the lesion (6.4 cm$^3$, Table 1).

The selection of this treatment protocol (total dose, dose per session, and number of sessions) was based on the knowledge of optic nerve tolerance to single-session radiosurgery$^{12,14,16,19,26,28}$ and experience treating the anterior optic pathways and other cranial nerves with multisession radiosurgery.$^{1,6,20}$ When using multisession radiosurgery, the the-
Radiosurgery for optic nerve sheath meningioma

TABLE 1
Summary of clinical characteristics and outcomes after radiosurgery

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (yrs), Sex</th>
<th>Optic Nerve Location</th>
<th>Presenting Symptom</th>
<th>Visual Acuity (Snellen)</th>
<th>Volume (cm³)</th>
<th>Outcome</th>
<th>Follow-Up (mos)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>42, F</td>
<td>lt</td>
<td>visual field loss</td>
<td>20/30</td>
<td>2.8</td>
<td>full restoration of visual fields &amp; acuity</td>
<td>42</td>
</tr>
<tr>
<td>2</td>
<td>45, M</td>
<td>rt</td>
<td>exophthalmos, visual field loss</td>
<td>20/40</td>
<td>6.4</td>
<td>full restoration of visual fields &amp; acuity</td>
<td>32</td>
</tr>
<tr>
<td>3</td>
<td>54, F</td>
<td>rt</td>
<td>visual field &amp; acuity loss</td>
<td>20/40</td>
<td>1.1</td>
<td>full restoration of visual fields &amp; acuity</td>
<td>30</td>
</tr>
</tbody>
</table>

Conclusions

Optic nerve sheath meningiomas are slow-growing tumors causing progressive loss of vision. Optimal management is controversial, but it appears that early intervention using SFRT or radiosurgery can achieve growth control and stop the progression of visual deficits. Multisession image-guided robotic radiosurgery is a novel treatment modality that combines the highest degree of conformality and accuracy with the capacity to deliver treatment in a frameless robotic delivery. Further studies expanding this preliminary experience are needed.

Fig. 4. Case 1. Left and right visual fields (left and right panels, respectively) obtained before (upper panels) and 36 months after (lower panels) treatment. Bilateral visual field deficits can be appreciated pretreatment, particularly affecting the left eye, where an ONSM was detected. Full restoration of visual fields was declared by an independent ophthalmologist.
eral sessions and improve the tolerance of the optic nerve to the irradiation. Further studies are required to assess the value of multisession radiosurgery compared with single-session radiosurgery and SFRT.

Disclosure

Dr. Romanelli has served in the past as a paid consultant for Accuray Incorporated. Dr. Wowra has served on Accuray’s clinical advisory board.

References

30. van den Bergh AC, Dullaart RP, Hoving MA, Links TP, ter Muzilly, 86077, Italy. email: radiosurgery2000@yahoo.com.